New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2 ...

Prostate and skin cancers are among the most common cancers affecting men. In Advanced Prostate Cancer, lifelong treatment ...

Scientists have uncovered a critical weakness in prostate cancer’s defences. The disease relies on two enzymes, PDIA1 and ...

Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy.

A groundbreaking new study has found that a combination of two drugs can boost survival rates in prostate cancer patients by ...

A multicenter clinical study in Austria has shown that a new, highly precise ultrasound approach can successfully target and treat early prostate cancer while preserving patients' quality of life.

Oncologists and urologists identified several barriers to treatment intensification for metastatic castration-sensitive ...

The FDA-approved drug Pluvicto offers hope for advanced prostate cancer patients, but access barriers remain despite proven ...

BALTIMORE, Nov. 13, 2025 (GLOBAL NEWSWIRE) — The Urology Care Foundation (UCF), the official foundation of the American Urological Association (AUA), and the Prostate Cancer Foundation (PCF) today ...

Black men choose aggressive prostate cancer treatment—regardless of anticipated life expectancy—more often than Hispanic or ...

A prostate cancer diagnosis and life during and after treatments can feel overwhelming. Alongside the shock of a diagnosis, ...